Research Article
Nimotuzumab in the Treatment of Inoperable Esophageal Tumors of Epithelial Origin
Table 2
General information of adverse events.
| | Categories for patients1and AE | Nimotuzumab treatment modalities | | Nimo no. (%) | Nimo + CT no. (%) | Nimo + RT no. (%) | Nimo + CT + RT no. (%) | Total no. (%) |
| | Patients with some AE | 10 (47.6) | 11 (52.4) | 8 (57.1) | 32 (72.7) | 61 (61) | | Patients with some nimotuzumab-related AE | 1 (4.8) | 2 (9.5) | 0 (0) | 4 (9.1) | 7 (7) | | Patients with some 3-4 severity degree AE | 2 (9.5) | 3 (14.3) | 3 (21.4) | 9 (20.5) | 17 (17) | | Patients with some nimotuzumab-related 3-4 severity degree AE | 0 (0) | 1 (4.8) | 0 (0) | 0 (0) | 1 (1) | | Patients with some serious AE | 3 (14.3) | 7 (33.3) | 2 (14.3) | 15 (34.1) | 27 (27) | | Patients with some serious nimotuzumab-related AE | 0 (0) | 1 (4.8) | 0 (0) | 1 (2.3) | 2 (2) | | Adverse events | 27 (100) | 31 (100) | 17 (100) | 154 (100) | 229 (100) | | Nimotuzumab-related AE | 2 (7.4) | 6 (19.4) | 0 (0) | 6 (3.9) | 14 (6.1) | | 3-4 severity degree AE | 2 (7.4) | 5 (16.1) | 3 (17.6) | 13 (8.4) | 23 (10) | | 3-4 severity degree nimotuzumab-related AE | 0 (0) | 1 (3.2) | 0 (0) | 0 (0) | 1 (0.4) | | Serious AE | 3 (11.1) | 10 (32.3) | 2 (11.8) | 24 (15.6) | 39 (17) | | Serious AE related to nimotuzumab | 0 (0) | 1 (3.2) | 0 (0) | 2 (1.3) | 3 (1.3) |
|
|
Nimo: nimotuzumab, CT: chemotherapy, RT: radiotherapy, AEs: adverse events. 1Subjects can be included in more than one category.
|
